Nabil Elhadi Omar

Hamad Medical Corporation - Doha / Qatar

Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences

AD Scientific Index ID: 5088155

Registration, Add Profile,
Premium Membership

Print Your Certificate

Nabil Elhadi Omar's MOST POPULAR ARTICLES

1-) Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)NE Omar, AIF Soliman, M Eshra, T Saeed, A Hamad, A Abou-AliESMO open 6 (6), 100315, 2021

2-) Stigma towards health care providers taking care of COVID-19 patients: A multi-country studyAJ Nashwan, GFD Valdez, ALF Sadeq, H Al-Najjar, H Elamir, M Barakat, ...Heliyon 8 (4), 2022

3-) Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature reviewAM Suliman, SA Bek, MS Elkhatim, AA Husain, AY Mismar, MZS Eldean, ...Cancer Immunology, Immunotherapy 70, 935-944, 2021312021

4-) Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: a systematic reviewNE Omar, KA El-Fass, AI Abushouk, N Elbaghdady, AEM Barakat, ...Frontiers in immunology 11, 1354, 2020262020

5-) Perceptions and expectations of health care providers towards clinical pharmacy services in a mental health hospital in QatarY Eltorki, O Abdallah, N Omar, M ZolezziAsian journal of psychiatry 42, 62-66, 2019252019

ARTICLES

Add your articles